Crinetics Pharmaceuticals (CRNX) Expected to Announce Quarterly Earnings on Thursday

Crinetics Pharmaceuticals (NASDAQ:CRNX) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.92) per share and revenue of $0.73 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Crinetics Pharmaceuticals Trading Down 6.7 %

Shares of CRNX opened at $32.30 on Wednesday. The firm has a market capitalization of $3.00 billion, a P/E ratio of -8.66 and a beta of 0.56. Crinetics Pharmaceuticals has a 12-month low of $31.84 and a 12-month high of $62.53. The firm has a fifty day moving average price of $42.31 and a 200-day moving average price of $50.41.

Insider Activity

In other news, insider Dana Pizzuti sold 5,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $39.07, for a total value of $195,350.00. Following the sale, the insider now directly owns 31,748 shares in the company, valued at approximately $1,240,394.36. This trade represents a 13.61 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.00% of the company’s stock.

Analysts Set New Price Targets

CRNX has been the subject of a number of recent analyst reports. Wolfe Research initiated coverage on shares of Crinetics Pharmaceuticals in a research note on Tuesday, February 4th. They set a “peer perform” rating for the company. JMP Securities reissued a “market outperform” rating and set a $87.00 target price on shares of Crinetics Pharmaceuticals in a research note on Monday, December 16th. TD Cowen initiated coverage on shares of Crinetics Pharmaceuticals in a research note on Tuesday, February 11th. They set a “buy” rating for the company. Citigroup boosted their target price on shares of Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and set a $81.00 target price on shares of Crinetics Pharmaceuticals in a research note on Monday, January 13th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $72.64.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.